We are live on ! Find out more
HA

HHLR Advisors Portfolio holdings

AUM $832M
1-Year Est. Return 32.38%
This Fund
S&P 500
This Quarter Est. Return
+50.61%
1 Year Est. Return
+32.38%
3 Year Est. Return
+137.31%
5 Year Est. Return
+86.76%
10 Year Est. Return
AUM
$10.9B
AUM Growth
+$3.52B
Cap. Flow
+$396M
Cap. Flow %
3.62%
Top 10 Hldgs %
72.03%
Holding
77
New
17
Increased
11
Reduced
16
Closed
3

Top Buys

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$406M
2
ZM icon
Zoom
ZM
+$119M
3
ARGX icon
argenx
ARGX
+$74.6M
4
PDD icon
Pinduoduo
PDD
+$68.3M
5
TSM icon
TSMC
TSM
+$58M

Top Sells

Rank Stock Value
1
JD icon
JD.com
JD
+$207M
2
VIE
Viela Bio, Inc. Common Stock
VIE
+$80.4M
3
ALGN icon
Align Technology
ALGN
+$62.2M
4
SNAP icon
Snap
SNAP
+$53.1M
5
SE icon
Sea Limited
SE
+$47.2M

Sector Composition

Rank Sector Weight
1 Healthcare 28.56%
2 Technology 23.22%
3 Consumer Discretionary 23.15%
4 Communication Services 14.32%
5 Consumer Staples 6.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MYOK
26
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$66.7M 0.61%
690,658
-285,329
-29% -$23.8M
SE icon
27
Sea Limited
SE
$72.5B
$64.2M 0.59%
598,489
-651,511
-52% -$47.2M
TSM icon
28
TSMC
TSM
$2.22T
$62.5M 0.57%
+1,100,495
New +$58M
KNSA icon
29
Kiniksa Pharmaceuticals
KNSA
$6.23B
$62.3M 0.57%
2,443,833
+547,945
+29% +$11.4M
GMAB icon
30
Genmab
GMAB
$21B
$50.8M 0.46%
1,500,000
OTIS icon
31
Otis Worldwide
OTIS
$27.2B
$34.9M 0.32%
+614,556
New +$31.8M
ALLO icon
32
Allogene Therapeutics
ALLO
$722M
$34.3M 0.31%
+800,000
New +$28.9M
LN
33
DELISTED
LINE Corporation
LN
$33.9M 0.31%
676,211
-195,045
-22% -$9.63M
ZLAB icon
34
Zai Lab
ZLAB
$3.01B
$32.9M 0.3%
400,000
-152,256
-28% -$10.3M
BEDU
35
DELISTED
Bright Scholar Education Holdings
BEDU
$31.3M 0.29%
996,449
LEGN icon
36
Legend Biotech
LEGN
$3.99B
$27.7M 0.25%
+650,000
New +$25.4M
NVAX icon
37
Novavax
NVAX
$1.49B
$27.2M 0.25%
+326,038
New +$12.5M
MLCO icon
38
Melco Resorts & Entertainment
MLCO
$1.97B
$26.4M 0.24%
1,698,877
-498,973
-23% -$7.72M
AKRO
39
DELISTED
Akero Therapeutics
AKRO
$26.3M 0.24%
1,056,673
+165,472
+19% +$3.78M
IGMS
40
DELISTED
IGM Biosciences
IGMS
$25.6M 0.23%
350,000
AMG icon
41
Affiliated Managers Group
AMG
$9.58B
$25M 0.23%
335,073
+28,430
+9% +$1.92M
ADCT icon
42
ADC Therapeutics
ADCT
$143M
$23.4M 0.21%
+500,000
New +$19M
FMTX
43
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$23.2M 0.21%
+500,000
New +$21.7M
GTHX
44
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$23M 0.21%
949,431
JOYY
45
JOYY Inc
JOYY
$3.66B
$21.2M 0.19%
+239,476
New +$16M
ARVN icon
46
Arvinas
ARVN
$604M
$21M 0.19%
625,000
-230,308
-27% -$9.78M
MOGU
47
MOGU Inc
MOGU
$15.3M
$18.8M 0.17%
870,581
RGNX icon
48
Regenxbio
RGNX
$619M
$16.8M 0.15%
456,000
RCUS icon
49
Arcus Biosciences
RCUS
$3.9B
$15.5M 0.14%
625,000
-142,128
-19% -$3.84M
NXTC icon
50
NextCure
NXTC
$27.6M
$13.7M 0.13%
53,192
-34,606
-39% -$13.2M

Similar funds

HHLR Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, HHLR Advisors held 77 positions worth $10.9B, up 47% from $7.42B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

HHLR Advisors deployed $396M of net new capital in Q2 2020, opening 17 new positions and adding to 11 existing holdings. Its largest new stake was TSMC: 1,100,495 shares worth $62.5M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was JD.com, an estimated $207M trimmed.

  • HHLR Advisors's largest Q2 2020 buy was TSMC: 1,100,495 shares worth $62.5M.
  • HHLR Advisors added most to Alibaba in Q2 2020, an estimated $406M increase.
  • HHLR Advisors's biggest Q2 2020 reduction was JD.com, cutting an estimated $207M.
  • HHLR Advisors fully exited Snap in Q2 2020, selling an estimated $53.1M.
  • HHLR Advisors's ten largest holdings make up 72% of its $10.9B portfolio in Q2 2020.
  • HHLR Advisors opened 17 new positions and closed 3 in Q2 2020.
  • HHLR Advisors's portfolio value rose 47% quarter-over-quarter to $10.9B.

Based on HHLR Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.